In recently issued human clinical study, Arjuna Natural Ltd.’s patented, high-potency curcumin formulation BCM-95 (Curcugreen) demonstrated the possibilities for efficiently managing Osteoarthritis symptoms. Pain is the key symptom of Osteoarthritis in which individuals seek medical care.
BCM-95 shows promising results as NSAIDs for reducing pain. None of the gastric side effects were observed during the clinical study. It is the first study of curcumin therapy, which shows a positive link to Osteoarthritis care.
Dhaneshwar Shep, at the City Care Accident Hospital, Parli Vaijnath, Maharashtra, India, led this random, open-label, parallel-arm study which was published in the Journal trials last March. 139 Osteoarthritis participants were given either 500mg BCM-95 three times daily, or 50mg diclofenac twice daily for 28 days.
BCM-95 demonstrated an ability to reduce pain and relieve joint stiffness, with secondary capacity to improve daily living functions, within two weeks of treatment. Curcumin suppresses pro-inflammatory cytokines and their release mediators to show its effect.
Benny Antony, joint managing director, Arjuna said “BCM-95 curcumin is a favourable alternative for treating OA symptoms than standard OTC drugs”.
BCM-95 has a GRAS status from US FDA, confirming its safety with 50 patents worldwide.
Mr Vinod Arora, Principal Advisor, IGMPI
Placement testimonials: Our alumni are working with Fortune 500 and global Pharmaceutical, Food and healthcare giants like